NR0B2 and liver cancer: Kinase-specific inhibitors for MAPK kinase (PD98059 and U0126), JNK kinase (SP600125), p38 kinase (SB203580), and PI3K (LY294002) were used to treat liver cancer cells HepG2 and Huh7, followed by qPCR-based NR0B2 mRNA measurement.